Tumor-specific antibody cocktail treatment suppresses colorectal tumor growth in mice.

ABSTRACT:

Background

Colorectal cancer (CRC) remains a leading cause of cancer-related mortality, with advanced-stage disease frequently marked by treatment resistance and recurrence. Tumor heterogeneity, driven by the accumulation of somatic mutations, undermines the efficacy of conventional therapies and limits the long-term success of targeted agents. There is an urgent need for new therapeutic strategies that can exploit, rather than be constrained by, this heterogeneity.

Methods

We developed a personalized immunotherapeutic pipeline in the syngeneic CT26 murine model of CRC. Briefly, whole exome sequencing identified mutated surface proteins (MSPs) unique to these cells. Of these MSPs, we selected 10 for the generation of MSP-specific polyclonal antibodies (pAbs). These pAbs were

SUBMITTER: Shukla GS 

PROVIDER: S-EPMC12936289 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature